Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC.

by Michael E Goldberg, Meagan Montesion, Lauren Young, James Suh, Joel Greenbowe, Mark Kennedy, Giuseppe Giaccone, Wallace L Akerley, Afshin Dowlati, Benjamin C Creelan, James K Hicks, Paul J Hesketh, Karen L Kelly, Jonathan W Riess, Vincent A Miller, Philip J Stephens, Garrett M Frampton, Siraj Ali, Jeffrey P Gregg, Lee A Albacker
Published 2018-01-01